<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726087</url>
  </required_header>
  <id_info>
    <org_study_id>CALIDAD-SVAO</org_study_id>
    <nct_id>NCT02726087</nct_id>
  </id_info>
  <brief_title>Quality of Life After Ministernotomy Versus Full Sternotomy Aortic Valve Replacement</brief_title>
  <acronym>QUALITY-AVR</acronym>
  <official_title>Health-related Quality of Life, Satisfaction and Outcomes After Ministernotomy Versus Full Sternotomy Aortic Valve Replacement. A Randomized Controlled Trial (QUALITY-AVR TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, single-blind, all comer, randomized controlled trial. Patients
      scheduled for isolated aortic valve replacement (AVR) due to aortic stenosis at &quot;Virgen de la
      Victoria Universitary Hospital&quot;, Málaga, Spain, will be eligible. Ninety-six patients will be
      randomly assigned to either partial upper sternotomy (ministernotomy, 48 patients) or full
      sternotomy AVR (48 patients). Sample size was determined for an Alpha error of 0.05,and Beta
      error of 0.1 for a power of 90% in detecting 0.10 difference points in quality of life
      EQ-5D-5L-index or 10 points in EQ-5D-5L-Visual Analogic Scale (QOL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, single-blind, all comer, randomized controlled trial. Patients
      scheduled for isolated aortic valve replacement (AVR) due to aortic stenosis at &quot;Virgen de la
      Victoria Universitary Hospital&quot;, Málaga, Spain, will be eligible. Ninety-six patients will be
      randomly assigned to either partial upper sternotomy (ministernotomy, 48 patients) or full
      sternotomy AVR (48 patients). Sample size was determined for an Alpha error of 0.05,and Beta
      error of 0.1 for a power of 90% in detecting 0.10 difference points in quality of life
      EQ-5D-5L-index or 10 points in EQ-5D-5L-Visual Analogic Scale.

      Inclusion criteria is severe aortic stenosis referred for medically indicated isolated aortic
      valve replacement due to aortic stenosis in patients &gt;18 years.

      Exclusion criteria are left ventricular ejection fraction less than 40%, previous cardiac
      surgery, urgent/emergent surgery, infective endocarditis, need of concomitant procedures
      other than isolated Morrow miectomy and thorax deformity.

      CE-marked and FDA-approved mechanical (Sorin Carbomedics®) and stented bioprosthetic aortic
      valves will be implanted (Carpentier Edwards Perimount® and Sorin Crown®). Perceval S
      Sutureless bioprosthetic valves (LivaNova®) could be used if needed in very small aortic
      annulus or high risk patients Quality of Life postoperative outcomes will be assessed, as QOL
      measurements and health status with the EQ-5D-5L® questionnaire (QOL index, health visual
      analogic scale, severity index and health index), repeatedly assessed preoperatively and
      postoperatively at 1-6-12 months. Clinical postoperative complications and outcomes will be
      registered at 1 month and 1 year as main secondary and safety end-point (combined end-point
      of 4 and 6 major complications) Patient Satisfaction will be assessed with a 20 question
      cardiac-surgery specific satisfaction questionnaire (SATISCORE®).

      Survival will be assessed at 1 year. Clinical pre and postoperative characteristics will be
      registered. Routine blood sampling will be performed pre- and postoperatively. All available
      data will be collected prospectively. Informed consent) will be obtained from patients
      meeting the inclusion criteria before the initiation of any study-specific procedures.

      The Institutional Review Board Ethic Comittee approved this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 20, 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences between intervention groups in change from baseline Questionnaire EQ-5D-5L® Index at 1, 6 or 12 months</measure>
    <time_frame>baseline-1-6-12 months</time_frame>
    <description>Questionnaire EQ-5D-5L® for quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences between intervention groups in change from baseline Questionnaire EQ-5D-5L® Visual Analogic Scale for pain at 1, 6 or 12 months</measure>
    <time_frame>baseline-1-6-12 months</time_frame>
    <description>Questionnaire EQ-5D-5L® for quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early postoperative combined endpoint of 6 complications</measure>
    <time_frame>1 month</time_frame>
    <description>All cause Mortality, acute myocardial infarction, cerebrovascular or transient ischemic accident, acute renal failure AKIN (acute kidney injury classification) greater or equal than 2, nosocomial infections (Pneumonia, early endocarditis, mediastinitis, sepsis) and need of any reintervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiscore Questionnaire</measure>
    <time_frame>1-6 months</time_frame>
    <description>Satisfaction in cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between intervention groups in change from baseline Questionnaire EQ-5D-5L® severity index at 1, 6 and 12 months</measure>
    <time_frame>baseline-1-6-12 months</time_frame>
    <description>Questionnaire EQ-5D-5L® for quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between intervention groups in change from baseline Questionnaire EQ-5D-5L® health index (severity index inverse) at 1, 6 and 12 months</measure>
    <time_frame>baseline-1-6-12 months</time_frame>
    <description>Questionnaire EQ-5D-5L® for quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late postoperative combined endpoint of 6 complications</measure>
    <time_frame>1-5 years</time_frame>
    <description>All cause Mortality, acute myocardial infarction, cerebrovascular or transient ischemic accident, acute renal failure AKIN (acute kidney injury classification) greater or equal than 2, nosocomial infections (Pneumonia, early endocarditis, mediastinitis, sepsis) and need of any reintervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total in-Hospital and Intensive Care Unit stay (in days)</measure>
    <time_frame>From date of surgery until the date of discharge or date of death from any cause, whichever came first, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary bypass time in minutes and cross-clamp ischemic heart time in minutes needed in the surgery</measure>
    <time_frame>day 1 after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilatory Support time needed after surgery (in hours)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusional requirements (number of red packed cells, fresh frozen plasma and platelets)</measure>
    <time_frame>First 72 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association functional class scale for heart failure</measure>
    <time_frame>baseline-1-6-12 months</time_frame>
    <description>To assess heart failure status between participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants alive (Survival)</measure>
    <time_frame>6-12 months</time_frame>
    <description>To assess first year mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants alive (Survival)</measure>
    <time_frame>5 years</time_frame>
    <description>To assess 5 year mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early postoperative combined endpoint of 4 complications</measure>
    <time_frame>1 month</time_frame>
    <description>All cause Mortality, acute myocardial infarction, cerebrovascular or transient ischemic accident, and acute renal failure AKIN (acute kidney injury classification) greater or equal than 2,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late postoperative combined endpoint of 4 complications</measure>
    <time_frame>1-5 years year</time_frame>
    <description>All cause Mortality, acute myocardial infarction, cerebrovascular or transient ischemic accident, and acute renal failure AKIN (acute kidney injury classification) greater or equal than 2,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>ministernotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimally invasive aortic valve replacement with Partial &quot;J&quot; upper hemisternotomy through right 4th intercostal space, performed according to current standard of care practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>full sternotomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Full sternotomy AVR through a standard median sternotomy, performed according to current standard of care practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ministernotomy</intervention_name>
    <description>Partial upper &quot;J&quot; hemisternotomy trough 4th right intercostal space)</description>
    <arm_group_label>ministernotomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Full sternotomy</intervention_name>
    <description>Conventional full median sternotomy</description>
    <arm_group_label>full sternotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Severe aortic stenosis defined as aortic valve area of less than 1 cm2 or index area
             of 0.6 cm2/m2 or mean gradient greater than 40 mmHg by echocardiography or double
             lesion with predominant stenosis.

          -  Referred for medically indicated aortic valve replacement

          -  Provide written informed consent

        Exclusion Criteria:

          -  Left ventricular ejection fraction less than 0.40

          -  Presence of any coexisting severe valvular disorder

          -  Previous cardiac surgery

          -  Urgent or emergent surgery

          -  Infective endocarditis

          -  Need for concomitant procedures other than isolated myectomy

          -  Severe COPD

          -  Severe thorax deformity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emiliano A Rodriguez-Caulo, MD,PhD,FECTS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Victoria, Málaga, spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emiliano A Rodriguez-Caulo, MD,PhD,FECTS</last_name>
    <phone>+34 951032054</phone>
    <email>erodriguezcaulo@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano A Rodriguez-Caulo, MD,PhD,FETCS</last_name>
      <phone>+34 951032054</phone>
      <email>erodriguezcaulo@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Emiliano A Rodríguez-Caulo, MD,PhD,FETCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Otero, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María José Mataró, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gemma Sánchez-Espín, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Porras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Such, MD,PhD,FETCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Guijarro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José María Melero, MD, FETCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José M Villaescusa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Begoña Vidal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2016</study_first_submitted>
  <study_first_submitted_qc>March 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</investigator_affiliation>
    <investigator_full_name>Emiliano Rodriguez-Caulo</investigator_full_name>
    <investigator_title>MD, PhD, FETCS</investigator_title>
  </responsible_party>
  <keyword>Ministernotomy</keyword>
  <keyword>aortic valve stenosis</keyword>
  <keyword>quality of life</keyword>
  <keyword>satisfaction</keyword>
  <keyword>cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

